3/17
11:43 am
zbio
Rating for ZBIO
Low
Report
Rating for ZBIO
3/17
11:43 am
zbio
Rating for ZBIO
Low
Report
Rating for ZBIO
3/17
08:57 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
3/17
08:57 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
3/17
08:01 am
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
3/17
07:55 am
zbio
Rating for ZBIO
Low
Report
Rating for ZBIO
3/17
07:55 am
zbio
Rating for ZBIO
Low
Report
Rating for ZBIO
3/16
09:04 pm
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
3/16
09:04 pm
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
2/10
08:05 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
1/6
10:42 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
1/6
10:42 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
1/5
04:00 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
1/5
04:00 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.